UNSPSC 51172165: Darifenacin hydrobromide

This classification denotes an antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CR02EYQ8GV. European Medicines Agency schedules Darifenacin hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21464. Darifenacin hydrobromide generally arises in the molecular formula C28H31BRN2O2. The term 'darifenacin hydrobromide' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule darifenacin hydrobromide under HS 29349990 and SITC 51579.

As of Q4 2014, DARIFENACIN HYDROBROMIDE remains US FDA's Preferred Term for this commodity. Darifenacin hydrobromide bears US NLM NCI C78068. SMILES: C1CCC(CC1)C(C2CCCCC2)([C@@H]3CCN(C3)CCC4CCC5C(C4)CCO5)C(=O)N.BR.

UNSPSC 51172165 Darifenacin hydrobromide is a Commodity code that in practice does not align with the recent state and local contracting activity tagged to it. The single recent opportunity — Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services — involves laboratory testing infrastructure, staffing, and immunoassay or confirmatory analysis (LC/MS/MS or GC/MS), not pharmaceutical procurement. The scope encompasses operation of two collection sites in Plano and McKinney, Interactive Voice Response systems for randomized testing notifications, and alternative testing methodologies including oral fluid and hair analysis, with no mention of darifenacin hydrobromide or any pharmaceutical product. The contract is estimated at $600,000 annually with a two-year term and three optional one-year renewals, structured on a per-test basis covering approximately 25,031 tests annually across five-panel and six-panel screening with confirmation services.

Collin County in Texas is the sole recent issuing body identified in the available records for this code. The RFP 2026-327 closed on July 23, 2026, with anticipated award on August 10, 2026. The code shows no evident activity from other state departments, counties, cities, school districts, transit authorities, or special-purpose districts. The mismatch between the code's pharmaceutical classification and the actual procurement being executed suggests either a tagging error or a material divergence between the UNSPSC assignment and the work being bought. Business development professionals evaluating this code should note that recent state and local solicitation activity does not reflect pharmaceutical supply; firms focused on darifenacin hydrobromide distribution should monitor other code families or verify assignment accuracy with issuing bodies before committing resources.